Skip to Content

BioNTech SE ADR BNTX

Morningstar Rating
$92.74 +1.50 (1.64%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

BioNTech's mRNA Technology Could Form the Foundation of a Future Economic Moat

BioNTech, founded in 2008 in Germany, has become a key player in the development of personalized mRNA cancer treatments. The emerging biotech's first commercial vaccine, for COVID-19, received its first authorization in December 2020, and its early-stage pipeline and mRNA technology platforms have caught the eye of several large pharmaceutical companies, resulting in collaborations and partnerships.

Price vs Fair Value

BNTX is trading at a 48% discount.
Price
$92.74
Fair Value
$961.00
Uncertainty
Very High
1-Star Price
$149.24
5-Star Price
$67.30
Economic Moat
Wsf
Capital Allocation
Rzsdtdqs

Bulls Say, Bears Say

Bulls

BioNTech's pipeline, which relies on expertise in mRNA and bioinformatics, will be difficult to replicate by competitors.

Bears

BioNTech's technology is still relatively new, with no oncology approvals to establish use in this setting.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BNTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$91.24
Day Range
$90.5292.81
52-Week Range
$88.00138.51
Bid/Ask
$94.02 / $94.30
Market Cap
$22.05 Bil
Volume/Avg
5,628 / 698,912

Key Statistics

Price/Earnings (Normalized)
7.31
Price/Sales
3.13
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
3.84%

Company Profile

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
5,700

Competitors

Valuation

Metric
BNTX
MRK
JNJ
Price/Earnings (Normalized)
7.3140.7215.28
Price/Book Value
1.037.735.27
Price/Sales
3.135.464.68
Price/Cash Flow
47.4316.1318.30
Price/Earnings
BNTX
MRK
JNJ

Financial Strength

Metric
BNTX
MRK
JNJ
Quick Ratio
9.990.830.91
Current Ratio
10.371.381.16
Interest Coverage
877.797.5918.88
Quick Ratio
BNTX
MRK
JNJ

Profitability

Metric
BNTX
MRK
JNJ
Return on Assets (Normalized)
12.85%7.38%13.98%
Return on Equity (Normalized)
14.68%18.18%35.02%
Return on Invested Capital (Normalized)
13.50%10.92%22.24%
Return on Assets
BNTX
MRK
JNJ
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRDnq$537.7 Bil
VRTX
Vertex Pharmaceuticals IncQzhybtt$108.4 Bil
REGN
Regeneron Pharmaceuticals IncCrvyjnp$104.6 Bil
MRNA
Moderna IncJxhkm$33.4 Bil
ARGX
argenx SE ADRDnl$23.7 Bil
ALNY
Alnylam Pharmaceuticals IncGzqmzns$19.5 Bil
BMRN
Biomarin Pharmaceutical IncWrmlmc$16.7 Bil
RPRX
Royalty Pharma PLC Class AJjkby$14.0 Bil
INCY
Incyte CorpMlqywgm$13.5 Bil

Sponsor Center